RxDoctor Payments Data

June Chih Liu, MD

Neurology · Arcadia, CANPI 1891768479

Payments from drug & device makers

$40,972in general payments, 2019–2025

Across 778 payments — averaging $52.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$17K
  • Amgen$2K
  • AbbVie$1K
  • Kyowa Kirin, Inc.$1K
  • Medtronic$1K
  • MDD US Operations, LLC$1K
  • plus $17K from 50 others

What the payments were for

  • Speaking & faculty fees$15,79339%
  • Travel & lodging$6482%
  • Food & beverage$24,18359%
  • Education$3481%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.70$16,633
Amgen(2 entities)63$1,714
AbbVie(2 entities)52$1,476
Kyowa Kirin, Inc.20$1,358
Medtronic13$1,316
MDD US Operations, LLC50$1,240
Neurocrine Biosciences, Inc.16$1,123
Gilead9$1,114
Acadia Pharmaceuticals Inc104$1,051
AstraZeneca(2 entities)20$996
SK Life Science, Inc.30$976
Eisai Inc.14$906
Sunovion Pharmaceuticals Inc.2$767
Amneal Pharmaceuticals LLC31$754
Lundbeck LLC28$726
UCB, Inc.23$681
Pfizer22$653
Alnylam Pharmaceuticals Inc.15$636
Lilly USA, LLC22$498
Abbott6$481
Grifols USA, LLC6$448
Avanir Pharmaceuticals, Inc.12$446
Esperion Therapeutics, Inc.9$423
Otsuka America Pharmaceutical, Inc.11$405
Regeneron Healthcare Solutions, Inc.6$342
Sanofi-aventis U.S. LLC7$333
Corium, LLC9$328
Novartis13$286
Amarin Pharma, Inc.13$281
Acorda Therapeutics, Inc14$274
GSK2$246
Biohaven Pharmaceutical Holding Company Ltd.8$205
Biohaven Pharmaceuticals, Inc.7$170
Impel Pharmaceuticals Inc.2$166
Madrigal Pharmaceuticals1$150
Phathom Pharmaceuticals, Inc.1$150
Lexicon Pharmaceuticals, Inc.2$148
Biogen6$133
Merz Pharmaceuticals, LLC4$130
Axsome Therapeutics, Inc.1$125
Zyla Life Sciences, Inc.9$123
Vertical Pharmaceuticals, LLC5$101
Tanabe Pharma America, Inc.3$71
Adamas Pharmaceuticals, Inc.3$65
Ipsen Biopharmaceuticals, Inc2$62
Boston Scientific2$49
Argenx US, Inc.1$33
Orphalan Inc1$30
Forte Bio-pharma LLC1$30
Mallinckrodt Hospital Products Inc.1$24
Neurelis, Inc.1$22
Ultragenyx Pharmaceutical Inc.1$20
Catalyst Pharmaceuticals, Inc.1$19
Bristol Myers Squibb1$18
Arbor Pharmaceuticals, Inc.1$16
Travere Therapeutics, Inc.1$1

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,972 in reported general payments places this provider in the 80th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$313,082
Medicare patients
544
Services billed
3,616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate135$807,181
RytaryCarbidopa/Levodopa267$344,276
AustedoDeutetrabenazine12$181,209
NeuproRotigotine134$146,226
XadagoSafinamide Mesylate67$90,212
Gamunex-CImmune Globul G/Gly/Iga Avg 4632$86,543
JardianceEmpagliflozin86$68,939
NourianzIstradefylline19$65,062
Repatha SureclickEvolocumab94$64,275
VascepaIcosapent Ethyl106$55,529
Nurtec OdtRimegepant Sulfate24$51,931
Rasagiline Mesylate112$25,680
OngentysOpicapone18$17,787
NamzaricMemantine Hcl/Donepezil Hcl11$16,968
FarxigaDapagliflozin Propanediol25$15,116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$1,051$807,181135 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$754$347,004339 claims
Teva Pharmaceuticals USA, Inc.Austedo$16,633$181,20912 claims
UCB, Inc.Neupro$681$146,226134 claims
Grifols USA, LLCGamunex-C$448$86,54332 claims
Kyowa Kirin, Inc.Nourianz$1,358$65,06219 claims
PfizerNurtec Odt$653$51,93124 claims
Neurocrine Biosciences, Inc.Ongentys$1,123$17,78718 claims
AbbVieNamzaric$1,476$16,96811 claims
AstraZenecaFarxiga$996$15,11625 claims
Arbor Pharmaceuticals, Inc.Edarbi$16$5,47116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,996 neurology providers in California.

Other neurology in Arcadia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →